These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 19450059

  • 21. Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries.
    Duran A, Spaepen E, Lamotte M, Walter E, Umuhire D, Lucioni C, Pinheiro B, Brosa M, Kutikova L, Pujol B, Van Belle S, Annemans L.
    J Med Econ; 2012; 15(3):409-18. PubMed ID: 22208527
    [Abstract] [Full Text] [Related]

  • 22. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A, Yee J, Gandra SR, Khan I, Petersen J.
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [Abstract] [Full Text] [Related]

  • 23. Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy.
    Berger A, Lord C, Corey-Lisle PK, Williams GR, Oster G.
    Clin Ther; 2012 Jun; 34(6):1350-63. PubMed ID: 22591754
    [Abstract] [Full Text] [Related]

  • 24. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 25. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 26. [Switch from Darbepoetin-alpha to Epoetin-alpha: cost and efficacy comparison for haemodialytic patients over one year follow-up in a single centre].
    Orazi E.
    G Ital Nefrol; 2008 Jan; 25(2):223-6. PubMed ID: 18350502
    [Abstract] [Full Text] [Related]

  • 27. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 Jan; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 28. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [Abstract] [Full Text] [Related]

  • 29. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM, Sheehan V, Shapiro MJ, Lottenberg L, Scarlata D, Audhya P, ASSESS Study Group and Amgen Inc.
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [Abstract] [Full Text] [Related]

  • 30. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
    Polsky D, Eremina D, Hess G, Hill J, Hulnick S, Roumm A, Whyte JL, Kallich J.
    Pharmacoeconomics; 2009 Dec; 27(9):755-65. PubMed ID: 19757869
    [Abstract] [Full Text] [Related]

  • 31. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.
    Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.
    Clin Ther; 2006 Oct; 28(10):1701-8. PubMed ID: 17157126
    [Abstract] [Full Text] [Related]

  • 32. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 33. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 34. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M, Décaudin B, Champs BB, Heran I, Urbina MA, Lemaitre V, Azar R, Odou P.
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [Abstract] [Full Text] [Related]

  • 35. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Aug; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 36. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
    Papachristos A, Kani C, Litsa P, Valsami G, Souliotis K, Saridi M, Markantonis S.
    Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
    [Abstract] [Full Text] [Related]

  • 37. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease.
    Padullés-Zamora N, Comas-Sugrañes D, Pineda-Yuste Mdel M, Jódar-Masanés R, Martínez-Castelao A.
    Nefrologia; 2012 May; 32(2):221-7. PubMed ID: 22421952
    [Abstract] [Full Text] [Related]

  • 38. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD.
    J Med Econ; 2008 May; 11(2):199-213. PubMed ID: 19450080
    [Abstract] [Full Text] [Related]

  • 39. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
    Arneson TJ, Li S, Gilbertson DT, Bridges KR, Acquavella JF, Collins AJ.
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
    [Abstract] [Full Text] [Related]

  • 40. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S.
    Clin Ther; 2014 Apr 01; 36(4):594-610. PubMed ID: 24656152
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.